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Beta-Blockers for Primary Prevention
of Heart Failure in Patients With Hypertension
Insights From a Meta-Analysis
Sripal Bangalore, MD, MHA, David Wild, MD, Sanobar Parkar, MD, MPH,
Marrick Kukin, MD, FACC, Franz H. Messerli, MD, FACC
New York, New York
Objectives This study sought to evaluate the efficacy of beta-blockers (BBs) for primary prevention of heart failure (HF) in
patients with hypertension.
Background The American College of Cardiology/American Heart Association staging for HF classifies patients with hyperten-
sion as stage A HF, for which BBs are a treatment option. However, the evidence to support this is unknown.
Methods We conducted a MEDLINE/EMBASE/CENTRAL search of randomized controlled trials that evaluated BB as first-
line therapy for hypertension with follow-up for at least 1 year and with data on new-onset HF. The primary out-
come was new-onset HF. Secondary outcomes were all-cause mortality, cardiovascular mortality, myocardial
infarction, and stroke.
Results Among the 12 randomized controlled trials, which evaluated 112,177 patients with hypertension, BBs reduced
blood pressure by 12.6/6.1 mm Hg when compared with placebo, resulting in a 23% (trend) reduction in HF risk
(p  0.055). When compared with other agents, the antihypertensive efficacy of BBs was comparable, which
resulted in similar but no incremental benefit for HF risk reduction in the overall cohort (risk ratio: 1.00; 95%
confidence interval: 0.92 to 1.08), in the elderly (60 years) or in the young (60 years). Analyses of secondary
outcomes showed that BBs confirmed similar but no incremental benefit for the outcomes of all-cause mortality,
cardiovascular mortality, and myocardial infarction but increased stroke risk by 19% in the elderly.
Conclusions In hypertensive patients, primary prevention of HF is strongly dependent on blood pressure reduction. When
compared with other antihypertensive agents, there was similar but no incremental benefit of BBs for the pre-
vention of HF. However, given the increased risk of stroke in the elderly, BBs should not be considered as first-
line agents for prevention of HF. (J Am Coll Cardiol 2008;52:1062–72) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.057h
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thronic heart failure (HF) is the only major cardiovascular
isease increasing in both incidence and prevalence, with
50,000 new cases diagnosed every year, affecting both
enders equally (1). The prevalence in the U.S. is increasing,
ith 50 HF patients per 1,000 people over the age of 65
ears (1). The increase in the incidence and prevalence of
F seem to parallel the increase in incidence and prevalence
f hypertension. The Framingham study has shown that
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Manuscript received October 26, 2007; revised manuscript received May 7, 2008,
ccepted May 13, 2008.ypertension has the greatest influence on the risk of future
F, accounting for 39% of HF in men and 59% in women
2,3). It confers a 2-fold higher risk of HF, carrying the
ighest population-attributable risk among all risk factors,
nd this risk increases in a graded continuous fashion with
ncrease in blood pressure (2–4). More than 90% of patients
See page 1073
ith HF have hypertension (3). The American College of
ardiology (ACC)/American Heart Association (AHA)
uidelines committee has recognized this important risk
actor; patients with hypertension are classified as stage A
F (those with risk factors for HF), and primary prevention
f overt HF (stage C HF) is important in this cohort (5).
Although hypertension is an important risk factor, its
reatment results in a 49% to 81% reduction in the risk of
eveloping HF (6). The ACC/AHA guidelines (5) state
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September 23, 2008:1062–72 Beta-Blockers and Heart Failurehat in patients at high risk for developing HF, systolic and
iastolic blood pressure should be controlled in accordance
ith contemporary guidelines, and beta-blockers (BBs) are
n option based on the 7th report of the Joint National
ommittee on hypertension (7). Although BBs are a
easonable option for patients with stage B HF (asymptom-
tic left ventricular dysfunction) caused by a prior myocardial
nfarction, its role in patients with stage B HF caused by left
entricular hypertrophy or in hypertensive patients with stage
HF is not well defined.
Messerli et al. (8) had documented nearly a decade earlier
hat although blood pressure was lowered by BBs, these
rugs were ineffective in preventing coronary artery disease
nd cardiovascular and all-cause mortality (odds ratio: 1.01,
.98, and 1.05, respectively) in patients with hypertension.
ther meta-analyses (9,10) and reviews (11) have noted
imilar results, resulting in withdrawal of endorsement for
hese medications as first-line therapy for hypertension by
ajor national and international guidelines (12,13). Despite
his, they remain the fourth-largest selling drug class in the
.S. (14). In a recent survey (15) in which physicians were
sked, “Which of the following class of drugs have been
roven to reduce the risk of stroke in hypertensive patients?”
Bs were by far considered the most effective class. Simi-
arly, when asked, “Which of the following classes of drugs
ave been proven to reduce mortality in hypertensive pa-
ients?” BBs were rated highest. These perceptions or
isperceptions are unfortunate and probably occur because
hysicians extrapolate their cardioprotective effects in HF
nd myocardial infarction to patients with uncomplicated
ypertension (16).
The beneficial effect of BBs for primary prevention of HF
n patients with hypertension is unknown. The objective of
he present analysis was to evaluate the efficacy of BBs for
revention of progression to overt HF in patients with
ypertension.
ethods
earch strategy. We conducted a MEDLINE/EMBASE/
ENTRAL search of studies using the terms: “beta adren-
rgic blockers,” “adrenergic beta antagonist,” “beta-
lockers,” and “hypertension.” We limited our search to
tudies in human subjects published in journals from 1966
o May 2008. We checked the reference lists of reviewed
rticles, prior meta-analyses, and original studies identified
y the electronic search to find other potentially eligible
tudies. Trials that were only in abstract form without an
rticle published were not considered for this analysis.
Eligible trials had to fulfill the following criteria to be
ncluded in this analysis: 1) randomized controlled trials
RCTs) to be included if they enrolled adult hypertensive
atients, both genders, with or without other cardiovascular
isk factors, with or without comorbidities but with no
stablished HF; 2) RCTs to be included if they evaluated
Bs as first line monotherapy both as intervention (i.e., vs. alacebo) or as comparator (i.e.,
s. other antihypertensive drugs);
) follow-up of at least 1 year;
nd 4) RCTs to be included if
hey assessed HF as an outcome,
eing primary or secondary, pre-
efined or analyzed post hoc.
election and quality assess-
ent. Three authors (S.B.,
.K., F.H.M) independently as-
essed trial eligibility and quality.
he quality of the trials was as-
essed based on the following: 1)
points for mixed studies and 1
oint for nonmixed studies—
ixed study indicates studies in
hich patients could be random-
zed to either a BB or a diuretic
n the BB arm, wherein it is
ifficult to separate the effects of
ndividual therapy; and 2) 1 point
f HF was considered a pre-defined end point and 0 points
f not.
ata extraction and synthesis. The primary outcome con-
idered for this analysis was new-onset HF as defined by the
rials. Secondary outcomes of interest were all-cause mor-
ality, cardiovascular mortality, myocardial infarction (fatal 
onfatal), and stroke (fatal  nonfatal) considered sepa-
ately. We extracted the inclusion/exclusion criteria, publi-
ation year, the sample size, age, first-line antihypertensive
gents used, blood pressure before randomization, blood
ressure at the end of the study, length of follow-up, and the
utcomes of interest for each of the studies listed earlier.
wo authors (S.B., S.P.) independently extracted all trial
ata in duplicate (  0.96).
tatistical analysis. Statistical analysis was done using
tandard software (Stata version 9.0, Stata Corp., College
tation, Texas) using the METAN program (17). The
ooled effect for each grouping of trials was derived from
he point estimate for each separate trial weighted by the
nverse of the variance (1/SE2). Heterogeneity was assessed
isually using funnel plots, Q (chi-square) statistics, and/or
he I2 statistics (18). If trials were homogeneous (p  0.05),
fixed-effect model was used to calculate pooled effect sizes.
therwise, a random-effect model of DerSimonian and
aird (19) was applied to calculate overall differences.
ublication bias was estimated using the weighted regres-
ion test of Egger. A subgroup analysis was performed to
valuate the role of BBs in the elderly versus the young. For
his analysis, we defined the younger cohort as studies in
hich the mean age of the population was60 years and an
lderly cohort as studies in which the mean age of the
opulation was 60 years. A sensitivity analysis was per-
ormed after excluding mixed BB/diuretic trials in which
atients could be randomized to either a BB or a diuretic
Abbreviations
and Acronyms
ACC  American College of
Cardiology
ACEI  angiotensin-
converting enzyme inhibitor
AHA  American Heart
Association
ARB  angiotensin
receptor blocker
BB  beta-blocker
CAD  coronary artery
disease
CCB  calcium-channel
blocker
CI  confidence interval
HF  heart failure
RCT  randomized
controlled trialgent in the BB arm of the trial. A pre-specified post hoc
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Beta-Blockers and Heart Failure September 23, 2008:1062–72nalysis was conducted to evaluate the effect of different BBs
nd the age of the study population (young vs. elderly).
eta-regression analysis. Univariate and multivariate re-
ression analyses were performed to evaluate predictors of
ew-onset HF in patients on BB. For the univariate analysis
he following covariates were considered: systolic and dia-
tolic pressure at entry and end of study, systolic and
iastolic pressure difference between the 2 treatment mo-
alities, age, and follow-up duration. The selection criterion
or multivariate regression analysis was based on univariate
tatistical significance and/or clinical judgment. The esti-
ated between-study variance (2) was calculated using an
stimate based on restricted maximum likelihood. The p
alue was considered significant at 0.05.
ower calculation. A power calculation was undertaken to
etermine whether the individual studies had adequate
ower to evaluate the beneficial effects of BB for the end
oint of HF. For a study to have 80% power, at a type I
rror rate of 5%, to detect a 30% relative risk reduction for
F with BB therapy (a reduction in the incidence of HF
rom 2.83% to 1.98%), there would need to be 5,099
atients in each arm of a 2-arm trial. The choice of a 2.83%
ncidence rate was based on the crude proportion from the
placebo-controlled trials.
esults
tudy selection. We identified 12 RCTs that fulfilled our
nclusion criteria (Fig. 1). We excluded the results from the
APHY (Metoprolol Atherosclerosis in Hypertension)
rial (20) because this was a subgroup from the HAPPHY
Heart Attack Primary Prevention in Hypertension) trial
21). There were 5 mixed BB/diuretics trials in which
atients could receive either a BB or a diuretic in the BB
rm of the trial (22–26). Three trials compared BB with
Figure 1 Selection of Studies
BB  beta-blocker; HTN  hypertension; RCT  randomized controlled trial.1lacebo (23,27,28), and 9 trials (10 arms) compared BB
ith other antihypertensive agents (21,22,24–26,29–32).
he antihypertensive agents evaluated in this analysis in-
luded diuretics (1 trial), angiotensin-converting enzyme
nhibitors/angiotensin receptor blockers (ACEI/ARBs) (4
rials) and calcium-channel blockers (CCBs) (5 trials). The
TOP-2 (Swedish Trial in Old Patients with hypertension-2)
rial had 2 comparison arms: 1 comparing BBs with ACEI and
he other comparing BBs with CCBs (25). The analysis for
ublication bias indicated no evidence of bias for any of the
nalyses (data not shown).
haracteristics of the trials. The baseline characteristics,
nclusion criteria, and quality assessment are summarized in
ables 1 and 2. The 12 RCTs evaluated 112,177 patients
ith hypertension, 55,060 (49%) patients randomized to the
B arm, 4,452 (4%) patients randomized to placebo, and
2,665 (47%) patients randomized to other antihypertensive
gents. The reported mean age of the patients in the trials
anged from 52 to 76 years, 56% (mean) of the patient
opulation were men, and patients were followed up for a
ean of 2.1 to 9 years. The definition of new-onset HF was
eterogeneous in these trials.
lood pressure-lowering effects. The average weighted
aseline systolic pressure of included participants was 172
8 mm Hg (range 149 to 197 mm Hg) with the diastolic
ressure (weighted) being 96  6 mm Hg (range 86 to 108
m Hg). When compared with placebo, BBs were more
ffective at reducing both systolic (weighted mean reduction
f 12.6  7.8 mm Hg) and diastolic pressures (weighted
ean reduction of 6.1  4.4 mm Hg). When compared
ith other antihypertensive agents, the antihypertensive
ffect of BBs was comparable (vs. diuretics 0.0/1.0 mm
g; vs. ACEI/ARBs 0.3/0.6 mm Hg; vs. CCBs 0.1/
0.7 mm Hg; negative numbers indicate that BBs were
ore efficacious than the comparison agent).
rimary outcome. Among the 112,117 participants in the
rials, 2,437 (2.2%) patients developed HF during a mean
ollow-up (weighted) of 4.4  1.2 years (range 2.1 to 9.0
ears): 1,202 (2.2%) patients in the BB group and 1,235
2.2%) patients in the comparison group (including
lacebo).
Bs versus placebo. In the 3 trials comparing BBs and
lacebo (23,27,28), there was trend toward a 23% reduction
n the risk of HF in the BB group compared with placebo
p  0.055) (Fig. 2). There was no heterogeneity in this
nalysis.
Bs versus other antihypertensive agents. In the trials
omparing BBs with other antihypertensive agents, the
ncidence of HF was comparable between the 2 groups (BB
s. others, 2.1% vs. 2.1%; p  0.91), thus failing to show a
uperiority of BBs over other antihypertensive agents (Fig. 3).
n the only trial comparing BBs with diuretics (HAPPHY)
21), there was a reduced incidence of HF in patients on
iuretic-based therapy compared with those on BB therapy,
ut this was not statistically significant (incidence 0.7% vs.
.0%; p  0.18). In the 4 trials comparing BBs with
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September 23, 2008:1062–72 Beta-Blockers and Heart FailureCEI/ARBs (25,26,29,30), there was no superiority of BBs
or the outcome of HF compared with ACEI/ARBs (inci-
ence 3.3% vs. 3.1%; p  0.36). Similarly, in the 5 trials
omparing BB with CCBs, there was no superiority for the
utcome of HF with BBs compared with CCBs (incidence
.8% vs. 1.9%; p  0.27) (Fig. 3). There was no heteroge-
eity in these analyses.
B type. Among the 9 trials (10 arms) comparing BBs
ith other antihypertensive agents, 5 trials enrolling 68,260
66%) patients used atenolol (22,29–32), whereas the re-
aining 4 trials enrolling 35,049 (44%) patients used mixed
Bs (atenolol or metoprolol or pindolol) (21,24–26).
ooled analysis of trials using atenolol failed to show a
uperiority of atenolol for the prevention of HF compared
ith other antihypertensive agents (incidence 1.8% vs. 1.7%;
 0.72) (Fig. 4). There was no heterogeneity in this
nalysis.
oung versus elderly. Among the 9 trials comparing BBs
ith other antihypertensive agents, 6 trials enrolling 87,210
83%) patients were in the elderly cohort (mean age 60
ears) (22,24,25,30–32), whereas 3 trial enrolling 18,312
17%) patients were in the younger cohort (mean age 60
eneral Characteristics of Included Trials
Table 1 General Characteristics of Included Trials
Trial Patient Characteristics
Versus placebo
Coope et al., 1986 (28) Adults (60–79 yrs) with SBP 170 or
DBP 105 mm Hg
IPPPSH, 1985 (27) Adults (40–64 yrs) with HTN and no CAD
STOP, 1991 (23) Adults (70–84 yrs) with HTN and without
prior MI/angina or stroke within prior
12 months
Versus diuretics
HAPPHY, 1987 (21) Men (40–64 yrs) with HTN without MI,
angina, CVA
Versus ACEI/ARBs
CAPPP, 1999 (26) Adults (25–66 yrs) with HTN without
renal disorders
LIFE, 2002 (30) Adults (55–80 yrs) with HTN and LVH
without MI or CVA in prior 6 months
STOP-2, 1999 (25) (ACEI arm) Adults (70–84 yrs) with HTN without MI or
CVA within prior 12 months
UKPDS, 1998 (29) Adults with HTN and DM
Versus CCBs
ASCOT, 2005 (31) Adults (40–79 yrs) with HTN and at least
one other CV risk factor but no CAD
CONVINCE, 2003 (22) Adults (55 yrs) with HTN and one other
CV risk factor (smoking, DM, prior CVD,
obesity)
INVEST, 2003 (32) Adults (50 yrs) with CAD and HTN
NORDIL, 2000 (24) Adults (50–59 yrs) with DBP 100 mm Hg
STOP-2, 1999 (25) (CCB arm) Adults (70–84 yrs) with HTN without MI or
CVA within prior 12 months
CEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; ASCOT A
rtery disease; CAPPP  Captopril Prevention Project trial; CCB  calcium-channel blocker; CON
VA  cerebrovascular accident; DBP  diastolic blood pressure; DM  diabetes mellitus; HA
ypertension; INVEST  INternational VErapamil SR and Trandolapril Study; IPPPSH  Internati
eduction trial; LVH  left ventricular hypertrophy; MI  myocardial infarction; NORDIL  Nordic
KPDS  United Kingdom Prospective Diabetes Study.ears) (21,26,29). There was no superiority of BBs for the primary outcome compared with other antihypertensive
gents, both in the elderly (incidence 2.3% vs. 2.3%; p 
.96) and in the younger cohort (incidence 1.2% vs. 1.2%;
 0.88) (Fig. 5). There was no heterogeneity in these
nalyses.
econdary outcomes. Compared with other antihyperten-
ive agents, BBs did not show any added benefit for any of
he secondary end points in the elderly (Fig. 6). In fact,
here was a 19% increased risk of stroke when compared
ith other antihypertensive agents. However, based on 3
rials in the younger cohort (60 years), there was no
ncreased risk of any of the secondary end points with a 22%
ecreased risk of stroke with BBs compared with other
ntihypertensive agents (Fig. 6). There was no heterogene-
ty in these analyses.
eta-regression analysis. Univariate meta-regression
nalysis showed that the relative risk of HF with BB therapy
ncreased with final attained systolic pressure (p  0.07)
Fig. 7), with systolic pressure difference between the
reatment modalities (p  0.0000004) (Fig. 8), and with
ength of therapy with BBs (p  0.0005) (Fig. 9). A
ultivariate meta-regression analysis identified systolic
N Follow-Up Beta-Blocker Comparison
884 4.4 Atenolol Open-control
,357 4.0 Oxprenolol Placebo
,627 2.1 Atenolol/metoprolol/pindolol/
HCTZ/amiloride
Placebo
,569 3.8 yrs Atenolol or metoprolol BFZ/HCTZ
,985 6.1 Atenolol or metoprolol/
HCTZ/BFZ
Captopril
,222 4.8 Atenolol Losartan
,418 5 Atenolol/metoprolol/pindolol/
HCTZ/amiloride
Enalapril or
lisinopril
758 9 Atenolol Captopril
,257 5.5 Atenolol Amlodipine
,476 3.0 Atenolol/HCTZ Verapamil
,576 2.7 Atenolol Verapamil SR
,881 4.5 Any diuretic/any beta-blocker Diltiazem
,409 5 Atenolol/metoprolol/pindolol/
HCTZ/amiloride
Felodipine/isradipine
candinavian Cardiac Outcomes Trial; BFZ bendrofluazide; BP blood pressure; CAD coronary
 Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints; CV  cardiovascular;
 Heart Attack Primary Prevention in Hypertension trial; HCTZ  hydrochlorothiazide; HTN 
ospective Primary Prevention Study in Hypertension; LIFE  Losartan Intervention for Endpoint
m trial; SBP  systolic blood pressure; STOP  Swedish Trial in Old Patients with hypertension;6
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Beta-Blockers and Heart Failure September 23, 2008:1062–72ignificant predictor of higher risk of HF with BB therapy
regression coefficient  0.092; 95% confidence interval
CI]: 0.001 to 0.183; p  0.04).
ensitivity analysis. We had 2 a priori hypotheses, the
ffects of BBs on primary outcome would be further
educed: 1) when studies using mixed BBs/diuretics are
xcluded (suggesting a dilution effect of these trials); and 2)
hen only high-quality studies are included.
A sensitivity analysis based on the quality criteria indi-
ated above showed no additional benefit of BBs for the
Figure 2 Risk Ratio for Heart Failure When Compared With Pla
The sizes of the data markers relate to weight of each trial. See Table 1 footnote
eneral Characteristics of Included Trials
Table 2 General Characteristics of Included Trials
Trial Age
Men,
%
Baseline BP
(mm Hg)
Versus placebo
Coope et al. (28) 69 31 196/99
IPPPSH (27) 52 100 173/108
STOP (23) 76 37 195/102
Versus diuretics
HAPPHY (21) 52 100 166/107
Versus ACEI/ARBs
CAPPP (26) 53 53 160/99
LIFE (30) 67 46 174/98
STOP-2 (25) (ACEI arm) 76 33 194/98
UKPDS (29) 56 54 159/94
Versus CCBs
ASCOT (31) 63 77 164/95
CONVINCE (22) 66 44 150/87
INVEST (32) 66 48 151/87
NORDIL (24) 60 49 173/106
STOP-2 (25) (CCB arm) 76 33 194/98
ee Table 1 footnote for expansions of trial names. *Mixed study indicates studies in which patien
nd 1 point for nonmixed studies. End point indicates whether heart failure was considered a pre
Abbreviations as in Table 1.utcome of HF with a trend toward 11% increased risk
ompared with other antihypertensive agents, confirming
ur a priori hypothesis (Fig. 10). Similarly, when the
nalysis was performed excluding mixed BB/diuretic trials,
here was no benefit of BBs over other antihypertensive
gents for the primary outcome of HF with a trend toward
% increased risk in patients on BBs. However when only
ixed BB/diuretic trials were included, there was a trend
oward a 5% decreased risk of HF with BBs, suggesting and
onfirming our a priori hypothesis of a dilution effect of
ansions of trial names. BB  beta-blocker; CI  confidence interval.
Study End BP
(BB-Placebo/Drug)
(mm Hg)
Quality Control
Mixed Study/End Point* Total Points
18.0/11.0 1/1 2
3.8/1.2 1/0 1
19.5/8.1 0/1 1
0.0/1.0 1/0 1
1.0/1.0 0/1 1
1.1/0.2 1/1 2
1.0/0.0 0/1 1
1.0/1.0 1/1 2
2.7/1.9 1/1 2
0.1/0.7 0/1 1
1 1/0 1
3.0/0.0 0/1 1
1.0/1.0 0/1 1
be randomized to either a beta-blocker (BB) or diuretic in the BB arm: 0 points for mixed studies
end point: 1 point if heart failure was considered an end point and 0 points if not.cebo
for expts could
t
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a
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w
w
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r
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September 23, 2008:1062–72 Beta-Blockers and Heart Failurehese trials. Similarly, excluding the mixed BB/diuretic trial
STOP) in the comparison with placebo, the trend toward
23% reduction in the risk of HF was no longer observed
risk ratio [RR]: 0.88; 95% CI: 0.57 to 1.34; p  0.544)
ith BBs. A subgroup analysis of high-risk cohorts (patients
ith left ventricular hypertrophy [30] or known coronary
Figure 4 Effect of Atenolol on the Risk of Heart Failure When C
The sizes of the data markers relate to weight of each trial. See Table 1 footnote
Figure 3 Risk Ratio for Heart Failure When Compared With Oth
The sizes of the data markers relate to weight of each trial. See Table 1 footnote
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blockrtery disease [CAD] [32] or diabetes [29] or those with1
dditional cardiovascular risk factors other than hyperten-
ion [22,31]) showed no superiority of BBs for the primary
revention of HF (Fig. 10).
Based on our power calculation, 5,099 patients are
equired in each arm of a trial for an 80% power and to show
ared With Other Antihypertensive Agents
ansions of trial names. CI  confidence interval.
tihypertensive Agents
ansions of trial names.
B  calcium-channel blocker; other abbreviations as in Figure 2.omp
for exper An
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Beta-Blockers and Heart Failure September 23, 2008:1062–7230% relative risk reduction of primary outcome with BB
herapy. Based on this criterion, 5 of the 9 trials (nonpla-
ebo) were sufficiently powered. Each of these individual
rials failed to show superiority of BBs for the primary
utcome over other antihypertensive agents: CAPPP (Cap-
opril Prevention Project) trial (26) (p  0.445), ASCOT
Anglo-Scandinavian Cardiac Outcomes Trial) (31) (p 
.137), CONVINCE (Controlled ONset Verapamil INves-
igation of Cardiovascular Endpoints) (22) (p  0.065),
NVEST (INternational VErapamil SR and Trandolapril
Figure 5 Risk Ratio for Heart Failure When Compared With Oth
The sizes of the data markers relate to weight of each trial. See Table 1 footnote
Figure 6 RR for Secondary Outcomes When Compared With Ot
CV  cardiovascular; MI  myocardial infarction; RR  risk ratio; other abbreviatiotudy) (32) (p  0.377), and NORDIL (Nordic Diltiazem
rial) (24) (p  0.321). Pooled analysis of these trials failed
o show a superiority of BBs for the primary outcome over
ther antihypertensive agents (RR: 0.93; 95% CI: 0.83 to
.05; p  0.249).
iscussion
his systematic review of RCTs investigated the efficacy of
Bs for the primary prevention of HF in patients with
tihypertensive Agents in Young Versus the Elderly Cohort
ansions of trial names. Abbreviations as in Figures 2 and 3.
ntihypertensive Agents
in Figure 2.er An
for expher A
ns as
h
B
t
e
o
c
s
c
B
p
a
f
s
m
p
p
p
t
p
d
s
t
o
(
a
L
a
e
e
t
B
A
s
m
l
o
p
a
r
o
(
a
n
o
H
b
m
a
l
1069JACC Vol. 52, No. 13, 2008 Bangalore et al.
September 23, 2008:1062–72 Beta-Blockers and Heart Failureypertension. The results of the present analyses show that
Bs provided an incremental benefit for HF risk reduc-
ion when compared with placebo (where they were more
ffective at reducing BP) but not when compared with
ther antihypertensive agents (where BP reduction was
omparable). Similarly, the risk reduction with BBs for
econdary outcomes was comparable but with an in-
reased risk of stroke in the elderly.
Bs, blood pressure reduction, and risk of HF. In
atients with left ventricular systolic dysfunction, BB ther-
py has been shown to improve left ventricular systolic
unction, reduce mortality, and improve exercise tolerance,
ymptoms and patient well-being (28,33–36). However, it
ust be emphasized that these beneficial effects are in
atients with established HF. There is a tendency among
Figure 7 Relative Risk of HF With BB
as a Function of SBP at Study End
The sizes of the data markers relate to weight of each trial. See Table 1 foot-
note for expansions of trial names. BB  beta-blockers; HF  heart failure;
SBP  systolic blood pressure.
Figure 8 Relative Risk of HF With BB as a Function of SBP Dif-
ference Between Treatment Modalities at Study End
The sizes of the data markers relate to weight of each trial. See Table 1
footnote for expansions of trial names. Abbreviations as in Figures 3 and 7.mhysicians to extrapolate the beneficial effects to primary
revention of HF in patients at high risk. However, no trial
o date has shown that monotherapeutic use of BBs in
atients with hypertension is associated with reduced car-
iovascular mortality and morbidity (8).
In a recent meta-analysis of 105,951 patients, BBs re-
ulted in a 16% higher incidence of stroke and no benefit for
he outcome of myocardial infarction in comparison with
ther antihypertensive agents including thiazide diuretics
9), attesting to and expanding on our observation made
lmost a decade earlier (8). However, this meta-analysis by
indholm et al. (9) did not evaluate the end point of HF,
nd some investigators have speculated that the deleterious
ffects on stroke prevention could be balanced by better
ffects on prevention of HF (37) and hence have continued
o endorse it.
lood pressure reduction and risk of HF. The ACC/
HA guidelines emphasize the importance of blood pres-
ure control to reduce the risk of HF. The result of this
eta-analysis echoes the importance of blood pressure
owering to reduce the risk of HF. The strongest predictor
f increased risk of HF with BBs was a significant blood
ressure difference with the comparator agent, i.e., as long
s BBs produced an equal reduction in blood pressure, the
elative risk reduction for HF was comparable to that of
ther antihypertensive agents. The BBs were efficacious
trend) when compared with placebo, where they resulted in
significant decrease in blood pressure. However, there was
o superiority of BB therapy (comparable efficacy) over
ther antihypertensive agents for the primary prevention of
F, both in the elderly and in the younger cohort where
lood pressure control was comparable. However, does this
ean that it does not matter how you lower blood pressure
s long as you lower it, to reduce the risk of HF? A closer
ook at the placebo-controlled studies shows that it may be
Figure 9 Relative Risk of HF With BB
as a Function of Length of Follow-Up
See Table 1 footnote for expansions of trial names. The sizes of the data
markers relate to weight of each trial. Abbreviations as in Figures 3 and 7.uch more than mere reduction in blood pressure. In the 3
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Beta-Blockers and Heart Failure September 23, 2008:1062–72lacebo-controlled studies (Coope et al. [28], IPPPSH
International Prospective Primary Prevention Study in
ypertension], STOP), BBs resulted in a mean blood
ressure decrease of 12.6/6.1 mm Hg compared with
lacebo, resulting in a trend toward 23% reduction in the
isk of HF. However, when the mixed BB/diuretic study
STOP) was excluded from the analysis, BBs resulted in a
ean blood pressure reduction of 10.9/6.1 mm Hg com-
ared with placebo, but with no significant reduction in the
isk of HF (RR: 0.88; 95% CI: 0.57 to 1.34; p  0.544)
eading one to speculate that the beneficial effect of BBs in
he placebo-controlled trial may have been the dilution
ffect of the mixed BB/diuretic study (STOP).
lood pressure reduction and risk of stroke. For the
imilar blood pressure reduction, there was excess stroke risk
ith BBs compared with other antihypertensive agents,
uggesting that for stroke prevention at least, not only
owering blood pressure but also the agent used is impor-
ant. The BBs differ in their effect on central aortic blood
ressure when compared with peripheral brachial pressure
38). When compared with ACEI, diuretics, and CCBs,
Bs do not lower central systolic blood pressure (38). For
he same peripheral blood pressure, a central aortic systolic
lood pressure 4.3 mm Hg higher and a central aortic pulse
ressure 3.0 mm Hg higher was noted with atenolol-based
reatment compared with the amlodipine-based treatment,
esulting in a 14% lower risk of coronary events and 23%
ower risk of stroke with CCBs in the CAFE (Conduit
rtery Functional Endpoint) trial (39). In our analyses, the
xcess stroke risk was seen only in the elderly cohort. In the
ounger cohort, however, BB therapy was associated with a
2% decreased risk of stroke. The result in the younger
ohort was heavily weighted by the CAPPP trial (76%
eight), which is a mixed BB/diuretic trial, and a dilution
ffect of this trial thus cannot be ruled out. More over, Khan
nd McAlister (40) have shown no benefit of BBs for
revention of stroke in the young (RR: 0.99; 95% CI: 0.67
Figure 10 Sensitivity Analysis: Effect of BB on the Risk of Hea
See Table 1 footnote for expansions of trial names. RR  risk ratio; other abbrevio 1.44). This analysis included the results from the ELSA dEuropean Lacidipine Study on Atherosclerosis) (41) trial
nd the MRC (Medical Research Council) trial (42), both
f which were excluded in the current analysis because they
id not report the outcome of HF. Including these 2 trials
for the stroke analysis) and excluding the results of the
APPP trial (mixed BB/diuretic trial) showed that in the
ounger cohort, BBs were associated with a nonsignificant
3% increased risk of stroke (RR: 1.23; 95% CI: 0.72 to 2.12;
 0.450; heterogeneity p  0.02) using a random-effects
odel. The beneficial effects of stroke prevention in the young
n our analysis should therefore be interpreted with caution.
rior studies. In the only other meta-analysis that ad-
ressed this question (still in abstract form), Elliot (43) in a
eta-analysis of 10 RCTs found that CCBs were inferior to
iuretic or BBs for the primary prevention of HF in patients
ith hypertension (RR: 1.32; 95% CI: 1.22 to 1.44; p 
.0001). However, the study was heavily weighted by the
LLHAT (Antihypertensive and Lipid-Lowering treat-
ent to prevent Heart Attack Trial) study, and the analysis
ncluded comparison of CCBs against either diuretics or
B. We have shown previously (44) and in this analysis
Fig. 10) that extrapolating the results from mixed BB/
iuretic trials to that of BBs is not ideal because these drug
lasses differ in their effects. The BBs have an increased risk
f stroke, whereas the same does not hold true for diuretics.
At first glance, our results contradict the results of the
PLTTC (Blood Pressure Lowering Treatment Trialists
ollaboration) trial (45), in which diuretics/BBs were supe-
ior to CCBs (RR: 1.33) at preventing HF, with a trend
avoring them in the comparison against ACEI (RR: 1.07).
owever it should be noted that in the analysis by BPLTTC,
of the 7 trials in the CCBs comparison groups and 2 of the
trials in the ACEI comparison groups were comparisons
gainst diuretic-based therapy, and any meaningful extrapola-
ion of these results to BBs may not be appropriate.
tudy limitations. As in other meta-analyses, given the
ack of data in each trial, we did not adjust our analyses for
lure When Compared With Other Antihypertensive Agents
as in Figure 2.rt Fai
ationsose of medications used nor for compliance to assigned
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September 23, 2008:1062–72 Beta-Blockers and Heart Failureherapy. In this analysis, similar to analyses by others, we
sed the mean age of the population to divide them into
ounger and elderly cohorts. This is not ideal, but given the
aucity of data in each of the trials this is probably
cceptable. Heart failure was a secondary end point in these
rials, and as such the trials may not be sufficiently powered
o evaluate this end point. Finally, the definition of new-
nset HF varied in these trials. Our search limitations and
ailure to evaluate/report HF outcomes in many of the
CTs may have introduced publication bias, although this
as not evident in the analyses for publication bias. It
hould be noted that 66% of patients on BBs were on
tenolol, hence meaningful extrapolation of these results to
hose of other BBs cannot be done.
onclusions
ur results echo the ACC/AHA guideline statement on the
mportance of blood pressure control to reduce the risk of
F in patients with hypertension in that BBs showed a
rend toward risk reduction of HF when compared with
lacebo, where they resulted in a significant decrease in
lood pressure. However, a significant decrease in blood
ressure in the placebo-controlled trials, excluding the
ixed BB/diuretic trial (STOP), failed to show any bene-
cial HF risk reduction with BBs, suggesting that a mere
eduction in blood pressure may not be sufficient and that
he type of medication used to lower it may be important as
ell.
When compared with other antihypertensive agents, BBs
rovided comparable but no incremental benefit for the
revention of heart failure. However, given the increased
isk of stroke in the elderly patients and lack of any
ncremental benefit for any of the primary or secondary
utcomes, BBs should not be used in the primary prevention
f HF, unless compelling circumstances such as prior
yocardial infarction were already present (11).
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